Invesco’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.3M Sell
182,002
-71,809
-28% -$963K ﹤0.01% 2482
2025
Q4
$4M Buy
253,811
+194,113
+325% +$2.47M ﹤0.01% 2346
2025
Q3
$715K Sell
59,698
-3,186
-5% -$25.5K ﹤0.01% 3084
2025
Q2
$475K Buy
62,884
+2,607
+4% +$15.7K ﹤0.01% 3175
2025
Q1
$333K Buy
60,277
+13,663
+29% +$84.4K ﹤0.01% 3320
2024
Q4
$268K Buy
46,614
+3,186
+7% +$30.5K ﹤0.01% 3450
2024
Q3
$450K Buy
43,428
+64
+0.1% +$837 ﹤0.01% 3277
2024
Q2
$562K Sell
43,364
-135
-0.3% -$1.82K ﹤0.01% 3226
2024
Q1
$759K Buy
43,499
+23,267
+115% +$308K ﹤0.01% 3123
2023
Q4
$190K Buy
20,232
+1,666
+9% +$15.5K ﹤0.01% 3580
2023
Q3
$207K Sell
18,566
-65,557
-78% -$1.06M ﹤0.01% 3579
2023
Q2
$1.8M Sell
84,123
-217,647
-72% -$6.42M ﹤0.01% 2667
2023
Q1
$12.2M Buy
301,770
+195,171
+183% +$9.32M ﹤0.01% 1641
2022
Q4
$4.96M Sell
106,599
-249,578
-70% -$11.4M ﹤0.01% 2252
2022
Q3
$18.5M Sell
356,177
-143,353
-29% -$8.38M 0.01% 1376
2022
Q2
$23.6M Buy
499,530
+157,523
+46% +$8.55M 0.01% 1269
2022
Q1
$24.3M Buy
342,007
+52,163
+18% +$3.39M 0.01% 1389
2021
Q4
$21.7M Buy
289,844
+183,676
+173% +$14.4M 0.01% 1500
2021
Q3
$6.03M Sell
106,168
-174,996
-62% -$8.65M ﹤0.01% 2286
2021
Q2
$12.4M Sell
281,164
-44,392
-14% -$2.17M ﹤0.01% 1921
2021
Q1
$16.1M Sell
325,556
-237,655
-42% -$11.9M ﹤0.01% 1682
2020
Q4
$23.7M Buy
563,211
+27,996
+5% +$1.23M 0.01% 1344
2020
Q3
$24.5M Buy
535,215
+419,312
+362% +$20.3M 0.01% 1212
2020
Q2
$5.82M Sell
115,903
-120,441
-51% -$6.23M ﹤0.01% 1914
2020
Q1
$12.2M Sell
236,344
-151,095
-39% -$8.05M 0.01% 1444
2019
Q4
$23.9M Buy
387,439
+57,499
+17% +$3.56M 0.01% 1325
2019
Q3
$19.8M Buy
329,940
+19,223
+6% +$1.43M 0.01% 1416
2019
Q2
$26.2M Sell
310,717
-102,610
-25% -$9.23M 0.01% 1297
2019
Q1
$39.5M Sell
413,327
-45,629
-10% -$4.09M 0.01% 920
2018
Q4
$32.5M Sell
458,956
-248,157
-35% -$19M 0.01% 934
2018
Q3
$60.4M Buy
707,113
+198,572
+39% +$19.9M 0.02% 794
2018
Q2
$58.9M Buy
508,541
+35,313
+7% +$3.52M 0.02% 779
2018
Q1
$38.3M Sell
473,228
-73,471
-13% -$5.65M 0.01% 860
2017
Q4
$32.1M Sell
546,699
-156,761
-22% -$7.85M 0.01% 963
2017
Q3
$32.9M Buy
703,460
+622,323
+767% +$25M 0.01% 948
2017
Q2
$2.92M Buy
81,137
+3,338
+4% +$107K ﹤0.01% 2281
2017
Q1
$2.4M Buy
77,799
+19,033
+32% +$593K ﹤0.01% 2461
2016
Q4
$1.97M Buy
58,766
+8,333
+17% +$239K ﹤0.01% 2590
2016
Q3
$1.34M Sell
50,433
-10,608
-17% -$246K ﹤0.01% 2796
2016
Q2
$1.35M Sell
61,041
-8,713
-12% -$228K ﹤0.01% 2727
2016
Q1
$2.05M Sell
69,754
-578,804
-89% -$16.1M ﹤0.01% 2455
2015
Q4
$21.4M Buy
648,558
+8,334
+1% +$272K 0.01% 1118
2015
Q3
$23.1M Buy
640,224
+71,015
+12% +$3.05M 0.01% 1067
2015
Q2
$25.6M Sell
569,209
-9,668
-2% -$376K 0.01% 1103
2015
Q1
$17.7M Buy
578,877
+483,067
+504% +$18.8M 0.01% 1250
2014
Q4
$4.87M Buy
95,810
+19,925
+26% +$892K ﹤0.01% 1928
2014
Q3
$3M Buy
75,885
+384
+0.5% +$15.3K ﹤0.01% 2278
2014
Q2
$3.25M Buy
75,501
+49,939
+195% +$1.9M ﹤0.01% 2271
2014
Q1
$1.02M Buy
+25,562
New +$929K ﹤0.01% 3015

Other funds holding ENTA

Invesco's ENTA Position: Q1 2026 in Review

Invesco reduced its Enanta Pharmaceuticals (ENTA) stake by 28% in Q1 2026, selling an estimated $963K and leaving 182,002 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2482.

Invesco first reported a position in ENTA in Q1 2014 and has held it in 49 quarters since. The position peaked at $60.4M in Q3 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Invesco held 182,002 shares of Enanta Pharmaceuticals worth $2.3M as of Q1 2026.
  • Invesco sold 71,809 Enanta Pharmaceuticals shares in Q1 2026, an estimated $963K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2482 holding.
  • Invesco first reported a position in Enanta Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
  • Invesco's Enanta Pharmaceuticals position peaked at $60.4M in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.